TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1359322

Group type: COMPARATOR
Intervention: Pentamidine 4 mg/kg intramuscular injections on alternate days (20 doses)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Amphotericin 0.5 mg/kg infused in 5% dextrose on alternate days (14 doses)
Number of subjects: 120
Study: 6332952

Group type: EXPERIMENTAL
Intervention: 1 day postoperative stay in the intensive care unit (Group I)
Number of subjects: 37

Group type: COMPARATOR
Intervention: 2 days postoperative stay in the intensive care unit (Group II)
Number of subjects: 37
Study: 31466703

Group type: EXPERIMENTAL
Intervention: High protein content formula
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reduced protein content formula
Number of subjects: 0

Group type: COMPARATOR
Intervention: Breastfeeding
Number of subjects: 0
Study: 28466679

Group type: EXPERIMENTAL
Intervention: 1000 IU/day vitamin D
Number of subjects: 92

Group type: COMPARATOR
Intervention: 400 IU/day vitamin D
Number of subjects: 92
Study: 27428671

Group type: EXPERIMENTAL
Intervention: trastuzumab emtansine (T-DM1)
Number of subjects: 602
Study: 24811145

Group type: EXPERIMENTAL
Intervention: Implementation of the computerized Intervention-Management-System (IMS)
Number of subjects: 0
Study: 21293163

Group type: EXPERIMENTAL
Intervention: Reduced-fluence verteporfin photodynamic therapy (PDT) with 25 mJ/cm², intravitreal ranibizumab 0.3 mg/0.05 ml, intravitreal dexamethasone 200 μg, and oral minocycline 100 mg daily for 3 months
Number of subjects: 19
Study: 19267407

Group type: EXPERIMENTAL
Intervention: Serum triglycerides (highest quartile)
Number of subjects: 31473

Group type: EXPERIMENTAL
Intervention: Serum triglycerides (after adjustment for BMI)
Number of subjects: 31473

Group type: COMPARATOR
Intervention: Total serum cholesterol, low-density lipoprotein cholesterol, HDL cholesterol
Number of subjects: 31473
Study: 16710715

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 15523353

Group type: EXPERIMENTAL
Intervention: 0.5 minimal phototoxic dose (MPD) 4 times/wk
Number of subjects: 18

Group type: COMPARATOR
Intervention: 1 MPD twice/wk
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 0.5 MPD twice/wk
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 0.75 MPD twice/wk
Number of subjects: 18
Study: 11397860

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: KTCZ (400 mg orally 4 times daily)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: KTCZ + transdermal testosterone (7.5 mg daily)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: KTCZ + transdermal estradiol (0.05 mg daily)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: KTCZ + testosterone + anastrazole (5 mg orally twice daily)
Number of subjects: 47
Study: 9269788

Group type: EXPERIMENTAL
Intervention: SDZ MRL 953
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 20
Study: 8342888

Group type: EXPERIMENTAL
Intervention: Modified expiratory technique
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard forced expiratory maneuver
Number of subjects: 48
Study: 3329489

Group type: EXPERIMENTAL
Intervention: Early excision-graft
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 0
Study: 935298

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 880

Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 880

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 880

Group type: COMPARATOR
Intervention: Any treatment (including placebo)
Number of subjects: 880
Study: 31134470

Group type: EXPERIMENTAL
Intervention: Fluoride dentifrice (500 ppm F, n=42)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: CPP‐ACP crème (10% w/v, n=35)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Fluoride dentifrice followed by CPP‐ACP crème (n=37)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 114
Study: 31615444

Group type: EXPERIMENTAL
Intervention: Citalopram (SSRI)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 33
Study: 28151887

Group type: EXPERIMENTAL
Intervention: Individualized contrast protocol
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard contrast protocol
Number of subjects: 100
Study: 25454283

Group type: EXPERIMENTAL
Intervention: WPHF NMES (100Hz, 1ms)
Number of subjects: 42

Group type: COMPARATOR
Intervention: CONV NMES (25Hz, 0.05ms)
Number of subjects: 42
Study: 22806087

Group type: EXPERIMENTAL
Intervention: Simulated obstructive hypopnea (inspiration through a threshold load)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Mueller maneuver
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: End-expiratory central apnea
Number of subjects: 41

Group type: COMPARATOR
Intervention: Normal breathing
Number of subjects: 41
Study: 21320256

Group type: EXPERIMENTAL
Intervention: Olanzapine treatment for mania and maintenance studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Olanzapine treatment for depression studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Olanzapine treatment in maintenance studies
Number of subjects: 0
Study: 19263034

Group type: EXPERIMENTAL
Intervention: Extended drotrecogin alfa (activated) 24 microg/kg/h
Number of subjects: 193

Group type: COMPARATOR
Intervention: Sodium chloride placebo
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Extended drotrecogin alfa (activated)
Number of subjects: 193
Study: 17672956

Group type: EXPERIMENTAL
Intervention: Demineralized bone matrix (DMBM)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Open-flap debridement (Control)
Number of subjects: 30
Study: 15041585

Group type: EXPERIMENTAL
Intervention: Rocuronium (undiluted)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Vecuronium (undiluted)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Rocuronium (1:1000 dilution)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Vecuronium (1:1000 dilution)
Number of subjects: 30
Study: 11561075

Group type: EXPERIMENTAL
Intervention: Nizatidine (600 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Famotidine (80 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9205013

Group type: EXPERIMENTAL
Intervention: Rapid atrial pacing
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Multivariate analysis
Number of subjects: 50
Study: 8435186

Group type: EXPERIMENTAL
Intervention: Gemfibrozil 600 mg twice daily
Number of subjects: 628

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 628
Study: 3315285

Group type: EXPERIMENTAL
Intervention: L-leucine (2-g oral dose)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (without L-leucine)
Number of subjects: 10
Study: 29352828

Group type: EXPERIMENTAL
Intervention: Zn-fortified filtered water (2.8 mg Zn/d)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Non-fortified filtered water
Number of subjects: 186
Study: 26786000

Group type: EXPERIMENTAL
Intervention: G‐hesperidin with 50 mg caffeine
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: G‐hesperidin with 75 mg caffeine
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: G‐hesperidin with/without caffeine
Number of subjects: 75
Study: 25695646

Group type: EXPERIMENTAL
Intervention: Real exposure to radiofrequency electromagnetic fields (EMFs)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 26
Study: 23021496

Group type: EXPERIMENTAL
Intervention: On-site rapid testing with risk reduction counseling
Number of subjects: 1281

Group type: EXPERIMENTAL
Intervention: On-site rapid testing without risk reduction counseling
Number of subjects: 1281

Group type: COMPARATOR
Intervention: Off-site referral for HIV risk reduction counseling and testing
Number of subjects: 1281
Study: 21042200

Group type: EXPERIMENTAL
Intervention: Bupivacaine plus buprenorphine for sciatic block
Number of subjects: 103

Group type: COMPARATOR
Intervention: Bupivacaine with epinephrine plus normal saline
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Bupivacaine sciatic block with intramuscular buprenorphine (0.3 mg)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Bupivacaine plus normal saline intramuscularly
Number of subjects: 103
Study: 18186954

Group type: EXPERIMENTAL
Intervention: Topical ketamine (0.4 mL, 20 mg) in 10 mL artificial saliva
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Topical ketamine (0.4 mL, 20 mg) + morphine (5 mL, 20 mg 4 per thousand) in 5 mL artificial saliva
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Topical morphine (5 mL, 20 mg 4 per thousand) in 5 mL artificial saliva
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (10 mL artificial saliva)
Number of subjects: 60
Study: 16444450

Group type: EXPERIMENTAL
Intervention: 20 mg/d pravastatin
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 40 mg/d pravastatin
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 42
Study: 15566456

Group type: EXPERIMENTAL
Intervention: Heparin infusion of 5000 U, starting 3 h before the administration of anti-neoplastic agents and continuing for 12 h
Number of subjects: 20

Group type: COMPARATOR
Intervention: Anti-neoplastic agents alone (Control)
Number of subjects: 20
Study: 11774859

Group type: EXPERIMENTAL
Intervention: Benidipine (once daily, 4 mg/d, in the morning)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Nifedipine (twice daily, 20 mg/d)
Number of subjects: 18
Study: 9032193

Group type: EXPERIMENTAL
Intervention: COPD patients
Number of subjects: 8

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 8
Study: 8344693

Group type: EXPERIMENTAL
Intervention: mAb IOT4A (0.6 mg, 1.2 mg, 2.4 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: mAb IOT4A (booster immunization)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: mAb IOT4A
Number of subjects: 10
Study: 3096820

Group type: EXPERIMENTAL
Intervention: modified 'CHAP II' regimen
Number of subjects: 19

Group type: COMPARATOR
Intervention: adriamycin and cis‐diamminedichloroplatinum
Number of subjects: 19

Group type: COMPARATOR
Intervention: tamoxifen, adriamycin, and cis‐diamminedichloroplatinum
Number of subjects: 19
Study: 31701153

Group type: EXPERIMENTAL
Intervention: Gradual nicotine reduction (15.5, 11.7, 5.2, 2.4, and 0.4 mg/g)
Number of subjects: 1250

Group type: EXPERIMENTAL
Intervention: Immediate nicotine reduction (0.4 mg/g)
Number of subjects: 1250

Group type: COMPARATOR
Intervention: Standard nicotine content cigarettes (15.5 mg/g; control)
Number of subjects: 1250
Study: 29752304

Group type: EXPERIMENTAL
Intervention: Eteplirsen 30 or 50 mg/kg IV once weekly
Number of subjects: 0
Study: 27602974

Group type: EXPERIMENTAL
Intervention: Econazole nitrate foam 1%
Number of subjects: 69

Group type: COMPARATOR
Intervention: Vehicle foam
Number of subjects: 69
Study: 25158932

Group type: EXPERIMENTAL
Intervention: Psychological interventions
Number of subjects: 82

Group type: COMPARATOR
Intervention: Drug treatments
Number of subjects: 82
Study: 22005962

Group type: EXPERIMENTAL
Intervention: New fixation technique using double anchors (group 1)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional technique (group 2)
Number of subjects: 28
Study: 20098307

Group type: EXPERIMENTAL
Intervention: Levofloxacin 1.5%
Number of subjects: 125

Group type: COMPARATOR
Intervention: Ofloxacin 0.3%
Number of subjects: 125
Study: 18284400

Group type: EXPERIMENTAL
Intervention: Tacrolimus gel 0.3%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tacrolimus cream 0.5%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calcipotriol ointment 0.005%
Number of subjects: 0
Study: 16368287

Group type: EXPERIMENTAL
Intervention: Early invasive strategy
Number of subjects: 1846

Group type: COMPARATOR
Intervention: ST deviation 0.05 to 0.09 mV
Number of subjects: 1846

Group type: COMPARATOR
Intervention: ST deviation > or = 0.10 mV
Number of subjects: 1846

Group type: COMPARATOR
Intervention: Troponin T 0.01 to 0.10 ng/mL
Number of subjects: 1846

Group type: COMPARATOR
Intervention: Troponin T > 0.10 ng/mL
Number of subjects: 1846
Study: 12502990

Group type: EXPERIMENTAL
Intervention: Continuous interscalene infusion of 2 mg/ml ropivacaine at 6 or 9 ml/h for 48 hours
Number of subjects: 24

Group type: COMPARATOR
Intervention: Initial interscalene block with 30 ml ropivacaine, 7.5 mg/ml (225 mg)
Number of subjects: 24
Study: 11142423

Group type: EXPERIMENTAL
Intervention: Low-fat, high-vegetable diet (12-week intervention)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Baseline diet (habitual Finnish diet)
Number of subjects: 85
Study: 8885726

Group type: EXPERIMENTAL
Intervention: Inpatient management with bed rest, weekly corticosteroids until 32 weeks, and ultrasonographic examination at 2-week intervals.
Number of subjects: 53

Group type: COMPARATOR
Intervention: Outpatient management with discharge after >72 hours of hospitalization, weekly corticosteroids until 32 weeks, and ultrasonographic evaluations.
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Inpatient management
Number of subjects: 53

Group type: COMPARATOR
Intervention: Outpatient management
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Cost analysis based on maternal hospital days
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 53
Study: 1550636

Group type: EXPERIMENTAL
Intervention: Spontaneous labor
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Spontaneous labor with oxytocin augmentation
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Oxytocin induction
Number of subjects: 112
Study: 6094450

Group type: EXPERIMENTAL
Intervention: 48 hours of prophylactic cefotaxime
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single dose of cefotaxime
Number of subjects: 0
Study: 31451065

Group type: EXPERIMENTAL
Intervention: HOME Program
Number of subjects: 302

Group type: COMPARATOR
Intervention: E‐CARE
Number of subjects: 302
Study: 29055489

Group type: EXPERIMENTAL
Intervention: NICE guidance on tumor necrosis factor inhibitor (TNFi) therapies
Number of subjects: 17505
Study: 27181456

Group type: EXPERIMENTAL
Intervention: Early strategy of renal-replacement therapy (initiated immediately after randomization)
Number of subjects: 620

Group type: COMPARATOR
Intervention: Delayed strategy of renal-replacement therapy (initiated based on specific criteria)
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: Early strategy of renal-replacement therapy
Number of subjects: 620

Group type: COMPARATOR
Intervention: Delayed strategy of renal-replacement therapy
Number of subjects: 620
Study: 25528663

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) dalteparin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 0
Study: 22851600

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.2 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sitagliptin 100 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuing Liraglutide 1.2 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuing Liraglutide 1.8 mg/day
Number of subjects: 0
Study: 20172652

Group type: EXPERIMENTAL
Intervention: Authorized deception
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-authorized deception
Number of subjects: 0
Study: 17575559

Group type: COMPARATOR
Intervention: Intravenous sitagliptin doses (25, 50, 100 mg)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Oral sitagliptin 100 mg after high fat meal
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Oral sitagliptin 100 mg fasted
Number of subjects: 22
Study: 16354317

Group type: EXPERIMENTAL
Intervention: Gemcitabine followed by docetaxel (1,000 mg/m2 for gemcitabine and 35 mg/m2 for docetaxel, given on days 1, 8, and 15 every 4 weeks)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Docetaxel followed by gemcitabine (35 mg/m2 for docetaxel and 1,000 mg/m2 for gemcitabine, given on days 1, 8, and 15 every 4 weeks)
Number of subjects: 147
Study: 12095002

Group type: EXPERIMENTAL
Intervention: Male simulated patients (SPs)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Female simulated patients (SPs)
Number of subjects: 56
Study: 12669741

Group type: EXPERIMENTAL
Intervention: Alendronate 5 mg/day
Number of subjects: 3021

Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg/day
Number of subjects: 3021

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3021

Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg
Number of subjects: 3021

Group type: EXPERIMENTAL
Intervention: Alendronate (general)
Number of subjects: 3021
Study: 7852533

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) substitution therapy (0.05 U/kg.day for 1 year; 0.03 U/kg.day during the first month)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 2182237

Group type: EXPERIMENTAL
Intervention: Anistreplase
Number of subjects: 1258

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1258
Study: 7191651

Group type: EXPERIMENTAL
Intervention: 15 mg of diazepam and 20 to 200 mg of methohexital intravenously
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: 12.5 mg of diazepam, 20 to 200 mg of methohexital, and 0.1 mg of fentanyl intravenously
Number of subjects: 124

Group type: COMPARATOR
Intervention: Saline placebo intravenously
Number of subjects: 124
Study: 31216398

Group type: EXPERIMENTAL
Intervention: Cardiovascular MRI-based strategy
Number of subjects: 918

Group type: COMPARATOR
Intervention: FFR-based strategy
Number of subjects: 918
Study: 28079501

Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg weekly
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 26786087

Group type: EXPERIMENTAL
Intervention: Debriefing session
Number of subjects: 35

Group type: COMPARATOR
Intervention: Lecture about BBN
Number of subjects: 35
Study: 25459211

Group type: EXPERIMENTAL
Intervention: Rapid weight loss (12-week program)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Gradual weight loss (36-week program)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Intention-to-treat analysis for rapid weight loss
Number of subjects: 204

Group type: COMPARATOR
Intervention: Intention-to-treat analysis for gradual weight loss
Number of subjects: 204
Study: 22989372

Group type: EXPERIMENTAL
Intervention: Repeated high‐dose bronchial allergen challenges with household dust mites for four consecutive days
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Repeated high‐dose bronchial allergen challenges
Number of subjects: 27
Study: 19889690

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 71
Study: 17972537

Group type: EXPERIMENTAL
Intervention: Adenosine stimulated tilt test (A‐HUT)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Nitroglycerine stimulated tilt test (NTG‐HUT)
Number of subjects: 41
Study: 15919301

Group type: EXPERIMENTAL
Intervention: Intraoperative saphenous vein duplex ultrasound scanning
Number of subjects: 58
Study: 11943949

Group type: EXPERIMENTAL
Intervention: Colchicine (1 mg/day, orally, 5 days/week)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Colchicine and Placebo
Number of subjects: 55
Study: 9813932

Group type: EXPERIMENTAL
Intervention: 6-inch paper spacer
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: 8-inch paper spacer
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: 10-inch paper spacer
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: standard 750 ml volumatic spacer
Number of subjects: 134
Study: 8137628

Group type: EXPERIMENTAL
Intervention: 200mg RU 486 followed by 5mg 9-methylene-PGE2 gel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 600mg RU 486 with 3mg or 5mg 9-methylene-PGE2 gel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 200mg RU 486 followed by 3mg 9-methylene-PGE2 gel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All treatment schedules
Number of subjects: 0
Study: 2573300

Group type: EXPERIMENTAL
Intervention: Terfenadine 60 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Terfenadine 120 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Terfenadine 180 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Terfenadine (all doses)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Terfenadine (active drug)
Number of subjects: 11
Study: 29719278

Group type: EXPERIMENTAL
Intervention: Clobazam (n=41)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Levetiracetam (n=31)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Lacosamide (n=96)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Pregabalin (n=25)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: AED Starts considered clinically beneficial
Number of subjects: 193

Group type: COMPARATOR
Intervention: AED Starts not clinically beneficial
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Clinically beneficial AED Starts
Number of subjects: 193
Study: 26507526

Group type: COMPARATOR
Intervention: IV TXA alone
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Combined IV and topical TXA
Number of subjects: 119
Study: 25625130

Group type: EXPERIMENTAL
Intervention: OFL (Optibond FL)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: OSP (Optibond Solo Plus)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: XTR (Optibond XTR)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: AIO (Optibond All-In-One)
Number of subjects: 35
Study: 23340559

Group type: EXPERIMENTAL
Intervention: Oral glutamine supplementation (twice daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment alone
Number of subjects: 0
Study: 20857137

Group type: EXPERIMENTAL
Intervention: Endurance training on a cycle-ergometer three times per week for 45 min at 70% of VO(2 peak) for 12 weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: Pre-training τVO(2p)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Normalized ∆[HHb]/VO(2p) ratio pre-training
Number of subjects: 14
Study: 18505181

Group type: EXPERIMENTAL
Intervention: APL 600 mg twice daily
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: APL 800 mg twice daily
Number of subjects: 147

Group type: COMPARATOR
Intervention: EFV (efavirenz)
Number of subjects: 147
Study: 16553341

Group type: EXPERIMENTAL
Intervention: Sevoflurane (45 patients)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Propofol (45 patients)
Number of subjects: 90
Study: 12776984

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 0